Calendar

Jan
6
Wed
Nasal Polyps Grand Rounds Enduring
Jan 6 2021 @ 12:29 am – Jan 6 2022 @ 1:29 am

Addressing the Type 2 Inflammation Signature Through the Management of CRSwNP

FACULTY

Stella Lee, MD
Assistant Professor
Department of Otolaryngology
Director, Division of Sino-nasal Disorders and Allergy
University of Pennsylvania Medical Center
Pittsburgh, Pennsylvania

RELEASE DATE: January 6, 2021

EXPIRATION DATE: January 6, 2022

View Activity

May
11
Tue
Enduring Activity: BREATHE Asthma AMCP Symposium – Dr. Mario Castro and Dr. Geoffrey Wall | Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View
May 11 2021 @ 9:12 am – May 11 2022 @ 10:12 am

Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View

View Activity

FACULTY

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical & Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas School of Medicine
Kansas City, KS

Geoffrey C. Wall, PharmD, FCCP, BCPS
John R. Ellis Distinguished Chair of Pharmacy Practice
Professor of Clinical Sciences
Director, Drake Drug Information Center
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Des Moines, IA

PROGRAM OVERVIEW

This enduring activity will cover the treatment and management of patients with moderate-to-severe asthma.


TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of US-based managed care professionals who manage or are involved with the care of patients with moderate-to-severe asthma.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Discuss the patient and healthcare system burdens associated with asthma
  • Explain how the underlying molecular pathophysiology of moderate-to-severe asthma informs targeted biologic therapies
  • Apply current medical committee guidelines and recommendations for the management of patients with moderate-to-severe asthma in clinical practice
  • Utilize findings from clinical trials of biologic therapies as add-on treatments in the maintenance setting for patients with moderate-to-severe asthma

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with moderate-to-severe asthma.
Credits: 1.0 ANCC Contact Hour.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Mario Castro, MD, MPH serves on the speaker bureau for AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi, and Teva. He receives fees as a consultant for Genentech, Teva, Sanofi-Aventis and Novartis. He contracted research from AstraZeneca, GlaxoSmithKline, Pulmatrix, Sanofi-Aventis and Shinogi. He receives grant funding from AstraZeneca, GlaxoSmithKline, Pulmatrix, and Sanofi-Aventis.

Geoffrey C. Wall, PharmD, FCCP, BCPS serves on the speaker bureau for Janssen Pharmaceuticals and Tetraphase Pharmaceuticals.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certification as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: May 11, 2021

EXPIRATION DATE: May 11, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/


ENDURING LEARNER NOTIFICATION

Med Learning Group
Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View – ENDURING
May 11, 2021 – May 11, 2022
Online

Acknowledgement of Financial Commercial Support
Sanofi Genzyme and Regeneron Pharmaceuticals

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-073-H04-P / JA4008163-9999-21-073-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives – After Attending This Program You Should Be Able To

  1. Discuss the patient and healthcare system burdens associated with asthma.
  2. Explain how the underlying molecular pathophysiology of moderate-to-severe asthma informs targeted biologic therapies.
  3. Apply current medical committee guidelines and recommendations for the management of patients with moderate-to-severe asthma in clinical practice.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below:

Name Relationship: Commercial Interest
Felecia Beachum NA
Mario Castro Speaker Bureau: AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi. Consultant: Genentech, Teva, Sanofi-Aventis and Novartis. Contracted Research: AstraZeneca, GlaxoSmithKline, Pulmatrix, Sanofi-Aventis, Shinogi.
Matthew Frese NA
Christina Gallo NA
Brianna Hanson NA
Scott McGee-Plys NA
Marcello Morgan NA
Geoffrey C. Wall Speaker Bureau: Janssen Pharmaceuticals, Tetraphase Pharmaceuticals
Lauren Welch NA

How to Get Your Certificate

  1. Go to http://mlg.cmecertificateonline.com
  2. Click on “Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View – ENDURING” link.
  3. Complete the post-test, click the provided link to go to the online evaluation site.
  4. Evaluate the meeting, click the provided link to open your credit certificate.
  5. Print/save all pages of your certificate for your records.

Questions?
Email Certificate@AmedcoEmail.com

View Activity

Oct
12
Tue
Individualizing the Management of Veterans with Severe Asthma
Oct 12 2021 @ 12:00 am – Oct 12 2022 @ 11:45 pm

Individualizing the Management of Veterans with Severe Asthma

 

PROGRAM CHAIR AND SPEAKING FACULTY

Sandra G. Adams, MD

Professor of Medicine, Pulmonary/Critical Care Division, UT Health San Antonio

Staff Physician, South Texas Veterans Health Care System

San Antonio, TX

View Activity

 

PROGRAM OVERVIEW

This activity will cover the assessment, monitoring, and treatment of patients with severe uncontrolled asthma within the Department of Veterans Affairs.

TARGET AUDIENCE

This educational activity is intended for pulmonologists, allergists, immunologists, and otolaryngologists and other healthcare professionals involved in the healthcare of patients with severe uncontrolled asthma within the Department of Veterans Affairs.

LEARNING OBJECTIVES

On completing the program, attendees should be able to:

  • Identify risk factors that predispose veterans and military personnel to severe asthma and poorer outcomes and apply best practices to improve health care in this population
  • Utilize phenotype- and endotype-specific biomarkers to diagnose, classify and manage severe uncontrolled asthma
  • Create individualized treatment plans for patients with severe asthma that incorporate evidence-based guidelines, patient-specific factors, and clinical trial data

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses who are involved in the assessment, monitoring, and treatment of severe uncontrolled asthma within the Department of Veterans Affairs.

CNE Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/ Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST 

Faculty Member Disclosure
Sandra G. Adams, MD Dr. Adams reports that she provides contracted research with unrestricted educational grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKlein, and Sunovion. She is also the President/Founder of WipeDiseases Foundation.

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer:

Douglas Cox, MSN, MHA, RN

Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Marcello Morgan, MD, MPH, Medical and Scientific Services for Med Learning Group has nothing to disclose.
  • Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures
  2. Participate in the enduring activity
  3. Complete posttest and evaluation form online.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Release Date: 10-12-2021
Expiration Date: 10-12-2022

Oct
15
Fri
Severe Asthma: Reducing Disease Burden with Step-Up Therapy
Oct 15 2021 @ 7:10 am – Oct 15 2022 @ 8:10 am


Severe Asthma: Reducing Disease Burden with Step-Up Therapy

View Activity

FACULTY

Geoffrey Chupp, MD
Professor of Medicine (Pulmonary)
Director, Yale Center for Asthma and Airways Disease (YCAAD)
New Haven, CT

Wanda Phipatanakul, MD, MS
Division of Asthma/Allergy and Immunology
Director of the Asthma/Allergy and Immunology Research Center
Professor of Pediatrics, Harvard Medical School
Boston, MA

Maureen George, PhD, RN, AE-C, FAAN
Professor of Nursing at CUIMC
Columbia University School of Nursing
New York, NY

PROGRAM OVERVIEW

This case-based live-virtual activity will cover the treatment and management of patients with severe asthma.

TARGET AUDIENCE

This CME activity is designed to meet the educational needs of pulmonologists, allergists, primary care physicians, pediatricians, and other healthcare providers involved in the management of patients with severe uncontrolled asthma.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess disease severity and intensify therapy as needed to manage the symptoms and quality-of-life issues associated with uncontrolled severe asthma in pediatric and adult patients
  • Utilize biomarkers and asthma phenotypes to personalize the selection of treatment options for pediatric and adult patients with severe asthma
  • Incorporate current treatment recommendations and clinical trial data for the management of severe asthma into clinical practice

ACCREDITATION STATEMENT

This program would be beneficial for nurses involved in the care of patients with severe asthma.
CNE credits: 1.0 ANCC Contact Hour.

CREDIT DESIGNATION STATEMENT

Med Learning Group will designate each virtual live meeting and simulcast for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the live-virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with severe asthma.
CNE credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Geoffrey Chupp, MD Dr. Chupp is a member of Speakers Bureau for GSK, AstraZeneca, Genentech, Regeneron, Sanofi, Teva, and Amgen.

Wanda Phipatanakul, MD Dr. Phipatanakul discloses that she has worked as a Consultant for Genentech, Novartis, Regeneron, Sanofi, Teva and GSK.

Maureen George, PhD, RN, AE-C, FAAN Dr. George is a consultant for AstraZeneca, Genentech, Sanofi Regeneron, and Teva. She also is a Speaker’s Bureau member for AstraZeneca, Genentech, and Teva.

Bridgette L. Jones, MD MS FAAAAI FAAP Dr. Jones receives fees for Non-CME/CE Services from Merck Manuals as a paid chapter author.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

CME Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Michael Page, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit, participants must:

  1. Read the CME/CNE information and faculty disclosures
  2. Participate in the online activity
  3. Complete posttest and evaluation form online.

Participants will receive their certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

RELEASE DATE: October 15, 2021

EXPIRATION DATE: October 15, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Oct
27
Wed
Grand Rounds Specialty Series Enduring – Severe Asthma: Reducing Disease Burden with Step-up Therapy
Oct 27 2021 @ 5:57 pm – Oct 27 2022 @ 6:57 pm


Grand Rounds Specialty Series Enduring – Severe Asthma: Reducing Disease Burden with Step-up Therapy

View Activity

PROGRAM CHAIR

Nicola A. Hanania, MD, MS, FRCP(C), FCCP, FACP, FERS, ATSF (PROGRAM CHAIR)
Director, Airway Clinical Research Center
Interim Chief, Pulmonary and Critical Care Medicine
Ben Taub Hospital, Baylor College of Medicine
Houston, TX

SPEAKING FACULTY

Michael Wechsler, MD
Professor of Medicine – National Jewish Health
Director, National Jewish Cohen Family Asthma Institute
Denver, CO

PROGRAM OVERVIEW

The case-based online activity will cover the treatment and management of patients with severe asthma.

TARGET AUDIENCE

This CME activity is designed to meet the educational needs of pulmonologists, allergists, primary care physicians, pediatricians, and other health care providers involved in the management of patients with severe uncontrolled asthma.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess disease severity and intensify therapy as needed to manage the symptoms and quality-of-life issues associated with uncontrolled severe asthma in pediatric and adult patients
  • Utilize biomarkers and asthma phenotypes to personalize the selection of treatment options for pediatric and adult patients with severe asthma
  • Incorporate current treatment recommendations and clinical trial data for the management of severe asthma into clinical practice

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group will designate each online activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with severe asthma.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT: Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Nicola A. Hanania, MD Discloses that he has received Consulting fees from GSK, Boehringer Ingelheim, Novartis, AstraZeneca, Sanofi, Teva and Amgen. He also has worked on the Speakers Bureau for AstraZeneca and Sanofi, and has received funds for contracted research from GSK, Boehringer Ingelheim, Novartis, Genentech, AstraZeneca, Sanofi and Teva

Michael Wechsler, MD Discloses that he has received consulting fees from AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron, Novartis, Genentech, Teva, Boehringer Ingelheim, Equillium and Amgen

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CME Content Review
The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Michael Page, PharmD, RPh, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

RELEASE DATE: October 27, 2021

EXPIRATION DATE: October 27, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Dec
1
Wed
Grand Rounds
Dec 1 @ 9:00 am – 10:00 am

Wednesday, December 1
9:00 – 10:00 AM

Location
TBA

Speaker
Hassan Nasir, DO

Dec
3
Fri
Grand Rounds @ Grand Junction, CO
Dec 3 @ 7:00 am – 8:00 am

Friday, December 3, 2021
7:00 – 8:00 AM

Location
Grand Junction, CO

Speaker
Hassan Nasir, DO

Jan
11
Tue
Grand Rounds @ Staten Island, NY
Jan 11 @ 8:00 am – 9:00 am

Tuesday, January 11, 2022
8:00 – 9:00 AM

Location
Staten Island, NY

Speaker
Sandra G. Adams, MD

Jan
12
Wed
Grand Rounds @ Richmond, IN
Jan 12 @ 7:30 am – 8:30 am

Wednesday, January 12, 2022
7:30 – 8:30 AM

Location
Richmond, IN

Speaker
Hassan Nasir, DO